RedHill Biopharma Ltd.
RDHL
Rank in Stocks
#32746
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its... RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Share Price
$0.395
Last synced: 2026-11-09
Market Cap
$1.24M
Change (1 day)
-7.69%
Change (1 year)
-61.27%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade RedHill Biopharma Ltd. (RDHL)
Category
Healthcare
EPS for RedHill Biopharma Ltd. (RDHL)
EPS as of June 2026 TTM: 0.00
According to RedHill Biopharma Ltd.'s latest financial reports, its current EPS (TTM) is 0.00. At the end of 2025 the company had an EPS of 0.00, an increase over its 2024 EPS of $-7.00.
EPS history for RedHill Biopharma Ltd. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | $-7.00 | -115.22% |
| 2023 | $46.00 | -107.67% |
| 2022 | $-600.00 | -40.00% |
| 2021 | $-1.00K | 0.00% |
| 2020 | $-1.00K | 42.86% |
| 2019 | $-700.00 | -17.65% |
| 2018 | $-850.00 | -34.62% |
| 2017 | $-1.30K | 18.18% |
| 2016 | $-1.10K | 15.79% |
| 2015 | $-950.00 | 58.33% |
| 2014 | $-600.00 | -29.41% |
| 2013 | $-850.00 | -15.00% |
| 2012 | $-1.00K | -37.50% |
| 2011 | $-1.60K | 547.77% |
| 2010 | $-247.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | - |
DE
|
|
| $6.08 | - |
DE
|
|
| $1.55 | - |
JP
|
|
| $3.66 | - |
CH
|
|
| $0.45 | - |
IL
|
Questions about RedHill Biopharma Ltd.'s earnings per share (EPS)
What was RedHill Biopharma Ltd.'s earnings per share (EPS) in 2025?
In 2025, RedHill Biopharma Ltd.'s earnings per share (EPS) was 0.00, compared with $-7.00 in 2024.
How has RedHill Biopharma Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, RedHill Biopharma Ltd.'s earnings per share (EPS) was highest in 2023 ($46.00) and lowest in 2021 ($-1.00K).
How does RedHill Biopharma Ltd.'s earnings per share (EPS) compare with similar companies?
RedHill Biopharma Ltd.'s earnings per share (EPS) (0.00) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.